Fig. 9
From: Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Reproduced with permission from ref [200]
Peptide targeted delivery of liposomes to modulate cytokine release in arthritis. a Schematic highlighting liposome components and in vivo delivery to arthritic rats. b Material characterization of ART-1-IL-27-liposomes. b1 and b2 illustrate the uniformity and monodispersity of the ART-1 targeted liposome by TEM and DLS respectively. c Zeta potential measurement to highlight positive induced charge following ART-1 incorporation. d Flow cytometry data corresponding to cellular uptake of ART-1-FITC-liposomes and Control-FITC-liposomes at 250 nM concentrations at various time points. Liposomes modified with ART-1 are capable of targeting and have better uptake efficiency than the control liposomes in vitro. e Real-time fluorescent imaging of naïve and arthritic rats 4 h post I.V. injection. There is increased accumulation in the arthritic joints of the rats with the ART-1 targeting ligand relative to the control. Naïve rats do not demonstrate particle accumulation. f Arthritic score of groups of rats treated with combinations of the ART-1-IL-27 liposome. The group that received with ART-1-IL-27-lipsosme demonstrate better recovery with a lower arthritic score than the control and groups treated with either ART-1 liposome, Control-IL-27 liposome, or Plain IL-27.